International Journal of Psychiatry in Clinical Practice最新文献_第2页

Evaluation of haematological parameters in patients with first-episode psychosis: distinctions between bipolar disorder and schizophrenia spectrum disorders. 首发精神病患者血液学参数的评估：双相情感障碍和精神分裂症谱系障碍的区别。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-05-11 DOI: 10.1080/13651501.2026.2669132

Eda Uzun Uysal, Ömer Alper Uysal, Bahri İnce

{"title":"Evaluation of haematological parameters in patients with first-episode psychosis: distinctions between bipolar disorder and schizophrenia spectrum disorders.","authors":"Eda Uzun Uysal, Ömer Alper Uysal, Bahri İnce","doi":"10.1080/13651501.2026.2669132","DOIUrl":"10.1080/13651501.2026.2669132","url":null,"abstract":"Background: Differences in blood cells and inflammatory markers occur during the first psychosis episode. Our study compared blood cell counts and inflammation markers among bipolar disorder, schizophrenia spectrum and healthy controls.Methods: The study involved 55 patients with schizophrenia spectrum disorders and 68 with bipolar disorder with psychotic features (manic episode), all hospitalised for a first psychotic episode with no prior psychiatric treatment, along with 61 age- and sex-matched healthy controls. Hemogram data from medical records were used, specifically those obtained within the first 48 h of hospitalisation.Results: Both patient groups had higher white blood cell, neutrophil, and monocyte counts than healthy controls. Patients with bipolar disorder had lower red blood cell counts, while schizophrenia patients showed lower eosinophil levels. Both groups also had elevated monocyte-to-lymphocyte ratios (MLR) compared to controls. No significant differences in blood cell counts or inflammatory markers were found between bipolar disorder and schizophrenia spectrum groups.Conclusions: Subtle Immune changes, including elevated MLR, monocytes and neutrophils, are observed in first-episode psychosis patients with bipolar disorder and schizophrenia spectrum diagnoses. Condition-specific findings, like decreased RBCs in bipolar disorder and eosinophils in schizophrenia, suggest unique early haematological profiles. These indicate low-grade inflammation may contribute to early psychotic disorders and underline the need for more longitudinal research.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"299-308"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atomoxetine and the risk of mania: a case report on bipolar disorder in an ADHD patient and its dilemmas. 托莫西汀与躁狂症风险：ADHD患者双相情感障碍病例报告及其困境。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-04-28 DOI: 10.1080/13651501.2026.2664103

Ekrem Furkan Uçak, Orçun Öztürk

{"title":"Atomoxetine and the risk of mania: a case report on bipolar disorder in an ADHD patient and its dilemmas.","authors":"Ekrem Furkan Uçak, Orçun Öztürk","doi":"10.1080/13651501.2026.2664103","DOIUrl":"10.1080/13651501.2026.2664103","url":null,"abstract":"Objectives: To investigate the potential role of atomoxetine in triggering manic episodes in a patient with ADHD and to explore diagnostic and therapeutic challenges posed by overlapping symptoms, temperament traits, and polypharmacy.Methods: We report the case of a 20-year-old male diagnosed with ADHD in childhood and treated long-term with atomoxetine and risperidone. Following a depressive episode after bereavement, the patient developed manic symptoms. The relationship between atomoxetine use, medication adjustments, temperament traits, and symptom onset was evaluated. The Naranjo Adverse Drug Reaction Probability Scale was used to assess causality.Results: Manic symptoms emerged while continuing atomoxetine (80 mg/day) and reducing risperidone to 1 mg/day due to its suspected depressogenic effects. The Naranjo score indicated a possible association between atomoxetine and mania onset. However, temperament characteristics and environmental stressors likely contributed to mood destabilisation. Mood stabilisation was achieved after initiating lithium.Conclusions: While the Naranjo score suggests a possible association between atomoxetine and mania, this episode may also represent the natural emergence of bipolar disorder. Atomoxetine might contribute to mood destabilisation in vulnerable individuals, particularly when concurrent antipsychotic doses are altered. Comprehensive monitoring of temperament and early mood instability is essential.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"325-327"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropsychiatric and behavioural correlates of sundowning in Alzheimer's disease. 阿尔茨海默病日落的神经精神和行为相关。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-03-16 DOI: 10.1080/13651501.2026.2642681

Antonina Luca, Maria Luca, Raffaele Ferri, Giuseppe Lanza, Alessandro Serretti

{"title":"Neuropsychiatric and behavioural correlates of sundowning in Alzheimer's disease.","authors":"Antonina Luca, Maria Luca, Raffaele Ferri, Giuseppe Lanza, Alessandro Serretti","doi":"10.1080/13651501.2026.2642681","DOIUrl":"10.1080/13651501.2026.2642681","url":null,"abstract":"Objectives: The aims of this study were to estimate the frequency of 'sundown syndrome' (SS) in a large sample of patients with Alzheimer's disease (AD) and to assess its associated socio-demographic and clinical variables.Methods: Three hundred and sixty-one AD patients (age 78.4 ± 8.3 years) collected within the National Institute of Mental Health Genetics Initiative were included. A subsample was autopsy-confirmed. SS was identified within a caregiver-structured interview. Sociodemographic, clinical and neuropsychiatric features of sundowners and non-sundowners were compared by logistic regression.Results: One hundred eighty-five patients (51.2%) were sundowners. SS was positively associated with several neuropsychiatric symptoms (i.e., hallucinations, suspiciousness, wandering and aggression; all p-values < 0.01), and negatively associated with Mini-Mental State Examination and voluptuary habits (all p values < 0.05). Subsample analysis carried out in the autopsy group confirmed the findings.Conclusions: SS is common in AD and is associated with several neuropsychiatric features and voluptuary habits. The identification of SS predictive factors may allow preventive and targeted therapeutic interventions.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"264-270"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies. 检查自闭症谱系障碍的神经视网膜改变：OCT和OCT- a研究的系统回顾。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-06-11 DOI: 10.1080/13651501.2026.2673918

David Vaquero-Puyuelo, Ana Boned-Murillo, Concepción De-la-Cámara, Antonio Lobo, Patricia Gracia-García, Francisco Javier Ascaso-Puyuelo, Javier Santabárbara

{"title":"Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies.","authors":"David Vaquero-Puyuelo, Ana Boned-Murillo, Concepción De-la-Cámara, Antonio Lobo, Patricia Gracia-García, Francisco Javier Ascaso-Puyuelo, Javier Santabárbara","doi":"10.1080/13651501.2026.2673918","DOIUrl":"10.1080/13651501.2026.2673918","url":null,"abstract":"Introduction: Autism Spectrum Disorder (ASD) affects around 1% of the population, and its diagnosis is primarily clinical. Therefore, the study of biological markers is essential. The retina and optic nerve have been studied in many ocular and non-ocular diseases using non-invasive techniques such as Optical Coherence Tomography (OCT) and OCT Angiography (OCT-A).Methods: A systematic literature search was performed using the Covidence® platform across promimnent databases including PubMed, PsycINFO and Embase up to February 2023.Results: The analysis of the included studies revealed differences in retinal parameters between individuals with ASD and neurotypical controls (NT). These variations encompassed changes in macular thickness and volume, RNFL thickness and volume, and in vascular perfusion and vessel density. Furthermore, certain changes were found to be correlated with clinical measures of ASD features.Conclusions: Current evidence reported diverse changes in neuroretinal parameters in ASD individuals. OCT and OCT-A have shown promising results in evaluating neuroretinal alterations in individuals with ASD. These techniques hold potential as biomarkers for early detection and monitoring of ASD. However, further research is necessary to fully explore the diagnostic and therapeutic potential of OCT and OCT-A in ASD population.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"244-255"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine. 治疗难治性抑郁症的药物增强：锂、喹硫平或艾氯胺酮治疗选择的神经生物学信息、实用决策指南。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-04-29 DOI: 10.1080/13651501.2026.2663307

David Eckert, Siegfried Kasper

{"title":"Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.","authors":"David Eckert, Siegfried Kasper","doi":"10.1080/13651501.2026.2663307","DOIUrl":"10.1080/13651501.2026.2663307","url":null,"abstract":"Objective: The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine.Methods: We conducted a narrative, non-systematic review, performing a targeted literature search on neurobiological mechanisms of action, clinical effects, and psychiatric, somatic, and practical decision-making factors. We considered international guidelines and supplemented them with clinical experience.Results: Lithium, quetiapine, and esketamine differ substantially in pharmacological profile, monitoring requirements, and clinical application. Although their mechanisms of action vary, they appear to converge on pathways related to neuroplasticity. Their distinct clinical characteristics may guide treatment selection depending on psychiatric presentation, somatic comorbidity, and practical feasibility.Discussion: All three agents represent augmentation strategies in TRD. A structured evaluation of clinical, somatic, and practical factors may support individualised treatment selection. However, validated predictive markers for differential response are currently lacking.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"235-243"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of premature treatment termination in an inpatient programme for women with PTSD and/or eating disorders. PTSD和/或饮食失调妇女住院方案中过早终止治疗的预测因素。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-06-01 DOI: 10.1080/13651501.2026.2677571

Fany Mershon, Jonathan E Handelzalts, Lotem Zvi, Inbal Shlomi

{"title":"Predictors of premature treatment termination in an inpatient programme for women with PTSD and/or eating disorders.","authors":"Fany Mershon, Jonathan E Handelzalts, Lotem Zvi, Inbal Shlomi","doi":"10.1080/13651501.2026.2677571","DOIUrl":"10.1080/13651501.2026.2677571","url":null,"abstract":"Objective: Premature termination of treatment (PTT) is prevalent among patients with eating disorders (ED) and post-traumatic stress disorder (PTSD). PTT is associated with negative outcomes. This study examined whether variables collected at admission and during hospitalisation predicted PTT among female patients treated for PTSD and/or EDs.Method: A total of 76 women hospitalised between 2019 and 2023 at the 'By Your Side' inpatient facility participated. PTT was defined as unplanned discharge without re-admission. Quantitative measures were analysed using t-tests and U-tests; qualitative measures were assessed using chi-square tests, followed by binary logistic regression.Results: A total of 97% of participants met DSM-5 Criterion A for trauma; 96% were diagnosed with PTSD, 74% with an ED and 70% with both. 43.4% terminated treatment prematurely. PTT was significantly associated with sexual risk-taking behaviours (χ2 = 4.601, df = 1, p = 0.032), impulsive departures from treatment (χ2 = 7.165, df = 1, p = 0.007) and fewer prior hospitalisations (B = 0.535, df = 1, p = 0.026). No differences were found in socio-demographic or clinical symptom scores. Outcomes were comparable between patients who left treatment and returned and those who remained continuously.Conclusions: Findings highlight the need to address impulsivity and risk-taking behaviours, and to support therapeutic re-engagement.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"315-324"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS. 治疗难治性抑郁症的速效方法：鼻内艾氯胺酮与加速rTMS的实际比较效果。

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-03-11 DOI: 10.1080/13651501.2026.2642680

Michele Prato, Matteo Carminati, Filippo Frizzi, Greta Verri, Mattia Tondello, Barbara Barbini, Cristina Colombo, Zanardi Raffaella

{"title":"Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS.","authors":"Michele Prato, Matteo Carminati, Filippo Frizzi, Greta Verri, Mattia Tondello, Barbara Barbini, Cristina Colombo, Zanardi Raffaella","doi":"10.1080/13651501.2026.2642680","DOIUrl":"10.1080/13651501.2026.2642680","url":null,"abstract":"Background: Treatment-Resistant Depression (TRD) often persists despite adequate pharmacotherapy. Intranasal Esketamine and accelerated repetitive Transcranial Magnetic Stimulation (aTMS) are rapid-acting options, but head-to-head comparisons remain limited.Methods: We conducted a retrospective study on TRD patients receiving either aTMS (n = 18) or Intranasal Esketamine (n = 22). Depression severity (Montgomery-Asberg Depression Rating Scale, MADRS) was assessed at baseline and 1, 3, and 6 months. Primary outcomes were response (≥50% MADRS reduction) and remission (MADRS <10). Longitudinal change was modelled with linear mixed-effects; moderators included clinical and demographics features.Results: At 1 month, aTMS showed higher response (72.2% vs 20%; p < 0.001) and remission (66.6% vs 10%; p = 0.0031) than Esketamine. Between-group differences were not significant at 3 months or 6 months. Mixed-effects models showed greater MADRS reduction with aTMS at 1 (p < 0.001) and 3 months (p = 0.007), but not at 6 months (p = 0.057). Psychiatric comorbidities were associated with greater improvement at 3 and 6 months within the Esketamine subgroup, with no analogous association in the aTMS subgroup.Conclusions: aTMS showed a stronger early antidepressant effect, but its advantage over esketamine progressively diminished and was no longer evident at six months. Prospective, well-powered comparative trials are required to validate these findings.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"256-263"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is pharmacotherapy guideline concordance consistent across patients who received pragmatic treatment for major depressive disorder? 在接受实用治疗的重度抑郁症患者中，药物治疗指南的一致性是否一致？

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-05-03 DOI: 10.1080/13651501.2026.2649617

Mason T Breitzig, Fan He, Lan Kong, Guodong Liu, Daniel A Waschbusch, Jeff D Yanosky, Erika F H Saunders, Duanping Liao

{"title":"Is pharmacotherapy guideline concordance consistent across patients who received pragmatic treatment for major depressive disorder?","authors":"Mason T Breitzig, Fan He, Lan Kong, Guodong Liu, Daniel A Waschbusch, Jeff D Yanosky, Erika F H Saunders, Duanping Liao","doi":"10.1080/13651501.2026.2649617","DOIUrl":"10.1080/13651501.2026.2649617","url":null,"abstract":"Objective: Pharmacotherapy guideline concordance for the treatment of major depressive disorder (MDD) is associated with improved symptom severity, but it is unclear whether such associations vary by patients' characteristics or their comorbidity burden. We sought to determine whether guideline concordance varied significantly by 1) sociodemographic characteristics or 2) comorbidity.Methods: This study evaluated 1,403 U.S. adults (67% female, 85% non-Hispanic/Latino White, mean age of 43 years) with non-psychotic MDD and complete data (n = 1,241/1,403). We used a guideline concordance algorithm (GCA-8) to measure pharmacotherapeutic concordance with the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines and multivariable general linear and proportional odds models to examine associations between this GCA-8 score and patients' characteristics.Results: Being male was significantly associated with higher guideline concordance, but guideline concordance did not vary significantly by any other sociodemographic characteristics. Similarly, no comorbidities examined by this study presented substantial evidence of associations with guideline concordance. Within this sample, the GCA-8 algorithm consistently measured the degree of guideline concordance across different patient types.Conclusions: This study suggests that guideline concordance for MDD pharmacotherapy, as measured by the GCA-8, does not significantly vary by the comorbidities or sociodemographic characteristics analysed in this study, except for patient-reported gender.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"271-279"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Depressive symptoms in patients with schizophrenia spectrum disorders and the impact on treatment motivation and satisfaction. 精神分裂症谱系障碍患者抑郁症状及其对治疗动机和满意度的影响

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-09-01 Epub Date: 2026-06-04 DOI: 10.1080/13651501.2026.2665275

Max Rothenberg, Sabine Lürzer, Edda Winkler-Pjrek, Nilufar Mossaheb, Fabian Friedrich, Dietmar Winkler

{"title":"Depressive symptoms in patients with schizophrenia spectrum disorders and the impact on treatment motivation and satisfaction.","authors":"Max Rothenberg, Sabine Lürzer, Edda Winkler-Pjrek, Nilufar Mossaheb, Fabian Friedrich, Dietmar Winkler","doi":"10.1080/13651501.2026.2665275","DOIUrl":"10.1080/13651501.2026.2665275","url":null,"abstract":"Objectives: Depressive symptoms are common in schizophrenia spectrum disorders and may influence how patients engage with treatment. This study examined whether depressive symptom severity affects motivation for treatment or satisfaction with inpatient care in patients with schizophrenia spectrum disorders.Methods: A total of 48 inpatients were divided into two groups: no or mild depressive symptoms (Group 1; N = 24) and moderate to severe depressive symptoms (Group 2; N = 24). Symptom severity was assessed at admission and discharge using the Hamilton depression rating scale and the positive and negative syndrome scale. Attitudes towards treatment (FPTM) were assessed at admission, and treatment satisfaction (ZUF-8) at discharge.Results: Treatment satisfaction was generally high and did not differ between depressive symptom groups. Greater depressive symptom severity was associated with higher mental distress. Higher initiative to engage in psychotherapy correlated positively with treatment satisfaction. Older age was also associated with greater satisfaction.Conclusions: Treatment satisfaction in schizophrenia spectrum disorders appeared largely independent of depressive symptom severity. In contrast, patients' motivation to engage in treatment was closely related to satisfaction, suggesting that motivation may play a more decisive role in shaping treatment experience than symptom severity alone. Early support of treatment motivation and further integrative research are warranted.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"309-314"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relation between serum oxytocin levels and impulsivity in patients under treatment for alcohol use disorder. 酒精使用障碍治疗患者血清催产素水平与冲动的关系

IF 2.3 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2026-08-25 DOI: 10.1080/13651501.2026.2722063

Aylin Çıklacoşkun, Tayfun Turan, Saliha Özsoy, Eser Kılıç, Ali Emre Köse

{"title":"Relation between serum oxytocin levels and impulsivity in patients under treatment for alcohol use disorder.","authors":"Aylin Çıklacoşkun, Tayfun Turan, Saliha Özsoy, Eser Kılıç, Ali Emre Köse","doi":"10.1080/13651501.2026.2722063","DOIUrl":"https://doi.org/10.1080/13651501.2026.2722063","url":null,"abstract":"Objective: Due to shared oxytocin pathways in impulsivity and alcohol use disorder (AUD), impulsivity is thought to increase susceptibility to AUD through the oxytocin system. This study investigated this relationship in patients under treatment for alcohol use disorder.Method: The study included 32 AUD patients and 34 healthy controls. First day of alcohol withdrawal, patients were assessed with the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) and the Hamilton Depression Rating Scale (HAM-D). On day 14, all these assessments were repeated along with the Michigan alcoholism screening test (MAST) and Barratt Impulsiveness Scale version 11 (BIS-11) then blood samples were taken to measure oxytocin levels. Only the HAM-D and BIS-11 scales were used in the control group, and blood samples were collected for oxytocin measurement.Results: The patient group had significantly lower oxytocin levels. The BIS-11 scores, including all subscales, were significantly higher in the patient group. A significant negative correlation was found between oxytocin levels and both the total BIS-11 score and the motor impulsivity subscale score in the patient group.Conclusion: These findings suggest that impulsivity may increase susceptibility to AUD through the oxytocin system. To better understand this relationship further research is needed.Key points: Serum oxytocin levels in the patient group were statistically significantly lower.All of the BIS-11 subscale scores and total BIS-11 score were statistically significantly higher in the patient group.A statistically significant negative correlation was found between the serum oxytocin levels, and the total BIS-11 score and motor impulsivity subscale score in the patient group.The results of this study are valuable in elucidating the role of impulsivity and oxytocin in AUD.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0